skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 73  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 next page
Refined by: Journal Title: Diabetes & Metabolism remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Material Type:
Article 		Add to My Research

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Diabetes & metabolism, 2018-12, Vol.44 (6), p.457-464 [Peer Reviewed Journal]

2018 Elsevier Masson SAS ;Copyright © 2018 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2018.09.005 ;PMID: 30266577

Full text available

Citations Cited by
2
Metformin and COVID-19: From cellular mechanisms to reduced mortality
Metformin and COVID-19: From cellular mechanisms to reduced mortality
Material Type:
Article 		Add to My Research

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Diabetes & metabolism, 2020-11, Vol.46 (6), p.423-426 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.07.006 ;PMID: 32750451

Full text available

Citations Cited by
3
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
Material Type:
Article 		Add to My Research

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

Diabetes & metabolism, 2019-06, Vol.45 (3), p.213-223 [Peer Reviewed Journal]

2019 Elsevier Masson SAS ;Copyright © 2019 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2019.01.008 ;PMID: 30708071

Full text available

Citations Cited by
4
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports
Material Type:
Article 		Add to My Research

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Diabetes & metabolism, 2020-09, Vol.46 (4), p.265-271 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.05.008 ;PMID: 32447101

Full text available

Citations Cited by
5
Glycemic Risk Index (GRI) variability in type 1 diabetes adults with HbA1c ≤ 7%: Insights for clinical evaluation and intervention
Glycemic Risk Index (GRI) variability in type 1 diabetes adults with HbA1c ≤ 7%: Insights for clinical evaluation and intervention
Material Type:
Article 		Add to My Research

Glycemic Risk Index (GRI) variability in type 1 diabetes adults with HbA1c ≤ 7%: Insights for clinical evaluation and intervention

Diabetes & metabolism, 2024-03, Vol.50 (2), p.101520-101520, Article 101520 [Peer Reviewed Journal]

2024 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2024.101520 ;PMID: 38309693

Full text available

Citations Cited by
6
Challenging 2019 ESC guidelines for the management of type 2 diabetes
Challenging 2019 ESC guidelines for the management of type 2 diabetes
Material Type:
Article 		Add to My Research

Challenging 2019 ESC guidelines for the management of type 2 diabetes

Diabetes & metabolism, 2020-06, Vol.46 (3), p.181-185 [Peer Reviewed Journal]

2019 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2019.10.006 ;PMID: 31707046

Full text available

Citations Cited by
7
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
Material Type:
Article 		Add to My Research

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes

Diabetes & metabolism, 2019-04, Vol.45 (2), p.110-121 [Peer Reviewed Journal]

2018 Elsevier Masson SAS ;Copyright © 2018 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2018.10.003 ;PMID: 30477733

Full text available

Citations Cited by
8
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
Material Type:
Article 		Add to My Research

Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists

Diabetes & metabolism, 2022-11, Vol.48 (6), p.101390-101390, Article 101390 [Peer Reviewed Journal]

2022 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2022.101390 ;PMID: 36170946

Full text available

Citations Cited by
9
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
Material Type:
Article 		Add to My Research

Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?

Diabetes & metabolism, 2022-03, Vol.48 (2), p.101325-101325, Article 101325 [Peer Reviewed Journal]

2022 Elsevier Masson SAS ;Copyright © 2022 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2022.101325 ;PMID: 35121148

Full text available

Citations Cited by
10
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
Material Type:
Article 		Add to My Research

The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection

Diabetes & metabolism, 2021-11, Vol.47 (6), p.101285-101285, Article 101285 [Peer Reviewed Journal]

2021 Elsevier Masson SAS ;Copyright © 2021 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2021.101285 ;PMID: 34597788

Full text available

Citations Cited by
11
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
Material Type:
Article 		Add to My Research

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations

Diabetes & metabolism, 2021-03, Vol.47 (2), p.101213-101213, Article 101213 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.11.005 ;PMID: 33249199

Full text available

Citations Cited by
12
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Material Type:
Article 		Add to My Research

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies

Diabetes & metabolism, 2023-09, Vol.49 (5), p.101474-101474, Article 101474 [Peer Reviewed Journal]

2023 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2023.101474 ;PMID: 37678760

Full text available

Citations Cited by
13
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies
Material Type:
Article 		Add to My Research

Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies

Diabetes & metabolism, 2021-11, Vol.47 (6), p.101220-101220, Article 101220 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.101220 ;PMID: 33359486

Full text available

Citations Cited by
14
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
Material Type:
Article 		Add to My Research

Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials

Diabetes & metabolism, 2020-06, Vol.46 (3), p.186-196 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.01.002 ;PMID: 32007623

Full text available

Citations Cited by
15
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Material Type:
Article 		Add to My Research

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

Diabetes & metabolism, 2015-06, Vol.41 (3), p.183-194 [Peer Reviewed Journal]

2015 ;Copyright © 2015. Published by Elsevier Masson SAS. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2015.02.003 ;PMID: 25794703

Full text available

Citations Cited by
16
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
Material Type:
Article 		Add to My Research

Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review

Diabetes & metabolism, 2024-03, Vol.50 (2), p.101508-101508, Article 101508 [Peer Reviewed Journal]

2023 ;Copyright © 2023. Published by Elsevier Masson SAS. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2023.101508 ;PMID: 38158077

Full text available

Citations Cited by
17
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Material Type:
Article 		Add to My Research

Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?

Diabetes & metabolism, 2023-03, Vol.49 (2), p.101419-101419, Article 101419 [Peer Reviewed Journal]

2023 ;Copyright © 2023. Published by Elsevier Masson SAS. ;Attribution - NonCommercial ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2023.101419 ;PMID: 36640828

Full text available

Citations Cited by
18
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
Material Type:
Article 		Add to My Research

Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers

Diabetes & metabolism, 2022-03, Vol.48 (2), p.101315-101315, Article 101315 [Peer Reviewed Journal]

2021 Elsevier Masson SAS ;Copyright © 2021 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2021.101315 ;PMID: 34910981

Full text available

Citations Cited by
19
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
Material Type:
Article 		Add to My Research

Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes

Diabetes & metabolism, 2021-11, Vol.47 (6), p.101275-101275, Article 101275 [Peer Reviewed Journal]

2021 Elsevier Masson SAS ;Copyright © 2021 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2021.101275 ;PMID: 34481962

Full text available

Citations Cited by
20
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
Material Type:
Article 		Add to My Research

Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors

Diabetes & metabolism, 2022-11, Vol.48 (6), p.101405, Article 101405 [Peer Reviewed Journal]

2022 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2022.101405 ;PMID: 36334794

Full text available

Citations Cited by

Results 1 - 20 of 73  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait